By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported that its second-quarter revenues increased to $800,000 from $225,000, which the firm attributed to initial fees and research revenues from certain collaborations.

The Tel Aviv, Israel-based drug discovery informatics and drug development firm posted a net loss of $896,000, or $.03 per share, for the three-month period ended June 30, compared to a profit of $2.4 million, or $.08 per share for Q2 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease.